Subject Index


Acute hepatic failure, artificial supports 313 (A) Acute renal failure
- - - - -, arteriovenous hemodiafiltration and
arteriovenous hemofiltration 33
- - - - -, blood purification in multiple system
organ failure 295 (A)
- - - - -, CAVH 283 (A), 306 (A), 309 (A)
- - - - -, CAVH treatment after cardiac surgery
315(A) Adolescents, treatment modalities in endstage renal
disease 4 AIDS, therapeutic and safety considerations in
apheresis procedures 51 Aluminum -, removal by polymethylmethacrylate membrane
286 (A) -, removal in CAPD after desferrioxamine 297 (A) Alveolar gas exchange, isovolemic
hemodialysis 41 Amiodarone, treatment of induced thyreotoxicosis
293 (A) Amyloid bone cysts, development in hemodialyzed
patients 308(A) Antistaphylococcal vaccination, CAPD 312 (A) Apheresis -, familial
hypercholesterolemia 298 (A)
- - procedures, AIDS 51
Ascites, treatment by dialytic ultrafiltration 252 Arteriovenous dialysis fistulas, hemodynamic
consequences 317 (A) Arteriovenous hemodiafiltration combined with
arteriovenous hemofiltration 33 Artificial kidney membranes, cardiopulmonary
effects in animal models 155 Atherosclerosis in maintenance dialysis patients
290 (A)
Beta-2-microglobulin
- - -, adsorption on dialysis membranes 284 (A)
- - -, clearances in CAVH 284(A)
- - -, effects of different dialyzers 314(A)
- - -, elimination by polyacrylonitrile hemofiltration
279(A) -, indicator of biocompatibility 278(A) -, kinetics and removal during hemofiltration
275 (A) -, kinetics during dialysis 307 (A) -, levels during hemodialysis 311 (A) -, predisposition to arthropathies in hemofiltration
and hemodialysis 306 (A)
- - -, removal during hemodiafiltration 281 (A)
- - -, removal during hemofiltration 288 (A), 289 (A)
- - -, removal by different membranes 279 (A),
281 (A), 286 (A), 289 (A), 305 (A), 316 (A) -, rise during hemodialysis 285 (A) Bicarbonate
concentrate, microbial contamination
299 (A) Bicarbonate hemodiafiltration, acid-base balance
272 (A) Bicarbonate kinetics, paired filtration dialysis
Bilirubin, adsorption by cholestyramine. Biocompatibility, artificial organs, beta-2-microglobulin as indicator for biocompatibility, cuprophan versus hemophan, dialyzer membranes in vitro and in vivo, different hemodialysis and plasmapheresis membranes, direct interactions of neutrophils with different membranes, membranes processes, phthalate-free hemodialysis tubings as alternative to bicarbonate dialysis, continuous computerized monitoring of hemodynamic parameters, mass transfer, blood purification, analysis of membrane processes, in vitro and in vivo, different hemodialysis and plasmapheresis membranes, direct interactions of neutrophils with different membranes, membranes processes.

Biofiltration, acetate-free, as alternative to bicarbonate dialysis, continuous computerized monitoring of hemodynamic parameters, mass transfer, blood purification, analysis of membrane processes, in acute renal failure with multiple organ failure, short time techniques, socioeconomic aspects in developing countries, blood purification systems, immobilized enzymes, Caffeine, hemodynamic effects in chronic renal failure, Cancer, double filtration plasmapheresis, CAPD, abdominal hernias, aluminum removal after desferrioxamine, antistaphylococcal vaccination.

Subject Index
325

HTLV HI antibody positive patients, interferon-γ and peritoneal macrophages, isolated ultrafiltration in diabetic nephropathy, kanamycin as marker of middle-molecular solute transport, large molecule removal, leukocyte tissue-type plasminogen activator, model of solute transport, peritoneal neutrophilia, positive H⁺ ion balance, safer connection device, vasopressin secretion, Cardiopulmonary bypass, damaging effects, Cardiopulmonary effects, membranes.


Cholestyramine, bilirubin adsorption, Ciclosporin A systemic lupus erythematosus, Continuous arteriovenous hemofiltration, see CAPD, Chronic ambulatory peritoneal dialysis, see CAVH, Cirrhosis, treatment of ascites with a hemofilter system, activation by different membranes.
288 (A), 289 (A) -, activation in hemodialysis 289 (A) -, activation in hemofiltration 288 (A) -, activation by plasma exchange and centrifugation technique 311 (A) -, artificial organs 100 -, fragments in hypersensitivity reactions during hemodialysis 292 (A) -, production of interleukin 270 (A) Complement split C 3d, extracorporeal circulation 162 Complications, short-term dialysis 193 Computer modelling, hemodialysis 278 (A) Continuous arteriovenous hemodialysis - -, acute renal failure 283 (A) - -, beta-2-microglobulin clearances 284 (A) Cryofiltration, prediction of clinical response 14 Cryoglobulinemia, double-filtration plasmapheresis 300 (A) Cuprophan - -, biocompatibility 262 -, cutaneous hypersensitivity in hemodialyzed patients 315 (A) Diabetes, hemodialysis 291 (A) Diabetic nephropathy - -, isolated ultrafiltration combined with CAPD 308 (A) - -, substitutive treatment in North-Western Italy 314 (A) Dialysate, bacterial contamination 284 (A) Dihydrotachysterol, immunity in hemodialyzed patients 303 (A) 25-Dihydroxycholecalciferol, immunity in hemodialyzed patients 303 (A) Edema, continuous arteriovenous hemofiltration 279 (A) Endotoxinemia, bacterial contamination of dialysate 284 (A) Endotoxins - -, in hemodialysis patients 280 (A) -, transport with high-flux membranes 202 End-stage renal disease, infants, children, adolescents 4 Erythropoietin - -, blood viscosity after treatment 277 (A) - -, treatment of anemia in hemodialyzed patients 309 (A) Ethylene oxide - -, antibodies in hemodialysis patients 292 (A) - -, cutaneous hypersensitivity in hemodialyzed patients 315 (A) Extracorporeal circulation, complement activation 162 First-use syndrome - -, hollow-fiber dialyzers 112 - -, limulus-amebocyte-lysatereactive material 115 Furosemide, intraperitoneal application in peritoneal dialysis 270 (A) 326 Subject Index Heart failure, treatment by ultrafiltration 309 (A) Hemodialysis - -, beta-2-microglobulin removal 281 (A) - -, long-term evaluation 282 (A) - -, plasma catecholamines and blood purification
303(A) Hemodialysis
amyloid bone cysts 308 (A)
analysis of membrane processes 202
atherosclerosis 290 (A)
autonomous hyperparathyroidism 269 (A)
beta-2-microglobulin levels and removal 279 (A), 281 (A), 314 (A), 316 (A)
blood gases and 2,3-DPG 302(A)
complement activation 100,123,162
computer modelling 278 (A)
continuous computerized monitoring of hemodynamic parameters 318 (A)
cutaneous hypersensitivity to cuprophan and ethylene oxide 315 (A)
density changes and chemotactic receptors of leukocytes 138
depressed natural killer cell function 305 (A)
in diabetic patients 291 (A)
double-lumen single needle 273 (A)
early complement activation 289 (A)
endotoxins 280 (A), 284 (A)
ethylene oxide antibodies 291(A)
first-use syndrome 115
gomostat artificial kidney 275 (A)
hypersensitivity reactions 292 (A)
immunoglobulin levels 310(A)
implantable jugular vein catheter 315 (A)
interleukin-1 activity 295 (A)
isovolemic in healthy man 41
jugular vein cannulation 275(A)
limbus-amebocyte-lysate-reactive material 115
lipid peroxidation 296 (A)
long-term complications of short-term treatment 193
mass transfer 272 (A), 282 (A)
microbial contamination of bicarbonate concentrate 299 (A)
neutrophil chemotaxis 24
paired filtration dialysis with two-chamber technique 283 (A)
parenteral nutrition 281(A)
patient’s view 1
phthalate-free tubings 272 (A)
prostaglandins 290 (A)
protein catabolism 269 (A)
racial, sexual and age discrimination 290 (A)
reuse and effective clearance of dialyser 296 (A) 
in series with hemofiltration and hemoperfusion 
297 (A)
-, short-time techniques 307 (A)
-, somatic and psychosocial prognostic indicators 
287 (A) -, sterile dialysate 306 (A) -, sterile dialysate and combination with CAPD 
273 (A) -, thyroid hormones and amiodarone-induced thyreotoxicosis 293 (A) -, in Turkey 286(A)
-, urea rebound and hypercatabolism 303 (A) -, vena cave inferior diameter and optimal dry weight 293(A) -
-, via a central catheter 304 (A) Hemofilter reuse, cost, safety, performance 256
Hemofiltration
-, analysis of membrane processes 202 -
alpha 2-microglobulin kinetics and removal 
275 (A), 279 (A), 288 (A) -, blood gases and 2,3-DPG 302(A) -
-, complement activation 288 (A)
-, hemofilter reuse 256 -
, in series with hemodialysis and hemoperfusion 
297 (A) -
, patient’s view 1 -
, thyroid hormones and amiodarone-induced thyreotoxicosis 293 (A) -
, treatment of cardiovascular complications 
294 (A) -
, urea kinetic modelling 283 (A) -
, very low-molecular-weight heparin 300 (A), 301 (A) -
, 9 years experience 302 (A) Hemoperfusion -
, in series with hemodialysis and hemofiltration 
297 (A) -
, thyroid hormones and amiodarone-induced thyreotoxicosis 293 (A) Hemophan, biocompatibility 262 Hemosorption -
, in end-stage renal failure and after transplantation 301 (A) -
, parameters of natural resistance 298 (A) -
, rapidly progressive glomerulonephritis 298 (A) Homeostat artificial kidney, personalized dialysis 
275 (A) Heparin -
, low molecular weight heparin for CAVH in children 317(A) -
, side effects of low molecular weight heparin 
278 (A) -
, very low molecular weight heparin in hemodialysis and hemofiltration 300 (A), 301 (A)
Subject Index
327
Hollow-fiber dialyzers, first-use syndrome 112 
HTLV III, positive antibodies in CAPD patients 308 (A) Hypercholesterolemia -
, LDLapheresis 298(A) -
, low-density lipoprotein plasma adsorption 
313(A) Hyperparathyroidism, in hemodialysis 269 (A) 
Immobilized enzymes, blood purification systems 
292 (A) Immunoadsorbents, in vitro testing 292 (A) Immunoglobulin, levels in hemodialyzed patients 
310(A) Infants, treatment modalities in end-stage renal disease 4 Interferon-peritonitis in CAPD patients 291 (A) 
-_
, activity in hemodialysis patients 295 (A) -, artificial organs 100 -, production using different membranes 270 (A) 
Jugular vein cannulation, hemodialysis 275 (A) Jugular vein catheter, hemodialysis 315 (A) 
Kanamycin, middle-molecular solute transport in
CAPD 291 (A) Killer cells, function in hemodialyzed patients
305 (A)
Large molecule removal, CAPD 280 (A)
Leukocyte tissue-type plasminogen activator, activity
in CAPD 290 (A) Leukocytes -, chemotactic receptors in hemodialysis and peritoneal dialysis 138 -, different membranes 276 (A) Limulus-amebocyte-lysate-reactive material, first-use
syndrome in hemodialysis 115 Lipid peroxidation, in hemodialysis 296 (A) Lipoprotein plasma adsorption, familial hypercholesterolemia 313 (A) Lupus nephritis, plasma exchange 304 (A) Lymphocyte proliferation, immunomodulatory effect of specific immune complexes 311 (A)
Macrophages, peritonitis in CAPD 291 (A)
Macrosolute charge, sieving coefficient 286 (A)
Malonyldialdehyde, production in platelets 313 (A)
Membrane - , adsorption of protein 316 (A)
-, cardiopulmonary effects in animal models 155
-, leukocytes, oxygen-free radical and complement 276 (A) -, protein catabolism 269 (A)
Membrane biocompatibility, platelet functionality 268 (A) Membrane plasmapheresis, analysis of membrane processes 202 Membrane processes, analysis for blood purification 202
Na⁺K⁺ pump, nuclear magnetic resonance 274 (A) Neutrophilia, CAPD patients 312 (A)
Neutrophils, chemotaxis after hemodialysis 24 Nuclear magnetic resonance, Na⁺K⁺ pump in uremia 274 (A)
Oxygen-free radical, production by different membranes 276 (A)
Paired filtration dialysis
- -, HCO₃ kinetics 268 (A)
- -, two-chamber technique 283 (A) Parathyroid hormone, bone formation in renal osteodystrophy with aluminum deposition 277 (A)
Parenteral nutrition, metabolic changes during hemodialysis 281 (A) Peritoneal dialysis
- -, density changes and chemotactic receptors of leukocytes 138
- , intraperitoneal furosemide 270 (A)
- , pharmacological modulation of transport rates 296 (A) Peritonitis, CAPD 291 (A) Phosphate, mass transfer during acetate and bicarbonate hemodialysis 272 (A) Phthalate-free hemodialysis tubings, biocompatibility 272 (A) Plasma exchange
- , active lupus nephritis 304 (A)
- , complement activation 311 (A)
- , rapidly progressive glomerulonephritis 274 (A)
- side effects using different substitution solutions 270 (A)
- thrombotic microangiopathy 310 (A)

Plasmapheresis
- cancer treatment 287 (A)
- cryoglobulinemia 300 (A)
- effects on rejection 285 (A)
- thyroid hormone detoxication 304 (A)
- thyroid hormones and amiodarone-induced thyrotoxicosis 293 (A)
Plate dialyzer, performance and safety of Gambro Lundia 10-5H 287 (A)
- malonyldialdehyde production 313 (A)
- membrane biocompatibility 268 (A)

Subject Index

Polyacrylonitrile, elimination of beta-2-microglobulin 279 (A)
Polyamide membrane, very effective beta-2-microglobulin removal 289 (A)
Polymethylmethacrylate membrane, aluminum and beta-2-microglobulin removal 286 (A)
Prostaglandins in maintenance dialysis patients 290 (A)
Protein catabolism, sham dialysis with different membranes 269 (A)
Protein A perfusion, basic investigations and first clinical experiences 179
Protein C, uremia 29
Rapidly progressive glomerulonephritis
- hemosorption 298 (A)
- immunosuppression and plasma exchange 274 (A)
Rejection, effects of plasmapheresis 285 (A)
Renal osteodystrophy, aluminum stain and parathyroid activity 277 (A)
Short-term dialysis, long-term complications 192
Sieving coefficient, macrosolute charge 286 (A)
Single needle, daily hemodialysis 273 (A)
Somatosensory evoked potentials, first dialysis 269 (A)
Sterile dialysate hemodialysis, combination with CAPD 273 (A)
Substitution solutions, side effects in plasma exchange 270 (A)
Systemic lupus erythematosus, ciclosporin A 271 (A)
Thrombotic microangiopathy, plasma exchange 310 (A)
Thyroid hormones
- detoxication by plasmapheresis 304 (A)
- effects of different blood purification methods 293 (A)
Ultrafiltration
- cardiovascular stability 271 (A)
- in healthy man 277 (A)
- treatment of heart failure 309 (A)
Urea kinetic modelling, hemofiltration 283 (A)
Uremia, defective protein C 29
Vasopressin, secretion in CAPD patients 271 (A)